Kristen M. Sanfilippo, MD, MPHS

Address: 

• Hematology Division
  Mail Stop 8125-0022-01, Washington University, 660 South Euclid Avenue, St. Louis, MO 63110 (mail)
• Suite 1101 Wohl Hospital (office)

Clinical Interest: Specializes in thrombosis medicine including venous thromboembolism; antiphospholipid antibody syndrome; anticoagulant therapy; hereditary thrombophilias; arterial thromboembolism with concern for thrombophilia; hereditary hemorrhagic telangiectasia; and vascular anomalies.

Research Interest: Research focuses on outcomes in persons with venous thromboembolism (especially cancer-associated thrombosis, pulmonary embolism, and antiphospholipid antibody syndrome); Anticoagulant-related bleeding; Antiphospholipid Antibody Syndrome; Hereditary Hemorrhagic Telangiectasia; and Vascular Anomalies. In addition to outcomes research in these populations, she also conducts clinical trials.

Involvement in Clinical Trials and Grants: Served as site PI for several multi-institutional trials, including NIH funded trials.

1. CANVAS multi-institute, randomized trial, Role – Site PI Washington University 2016-2020. Trial comparing treatment of cancer-associated thrombosis with standard of care versus DOAC (pragmatic trial). Within top 5 accruing sites. Enrollment complete. Publication submitted.
2. EVE muti-institute, double-blind randomized trial, Role – Site PI Washington University 2018-current. Trial comparing apixaban 5mg twice daily to 2.5mg twice daily for long-term treatment of cancer associated thrombosis after 6 months. Enrollment complete. Data undergoing analyses.
3. NIH ACTIV-4C double-blind, randomized trial, Role – Site PI Washington University 2021-current. Trial compares palcebo to low-dose apixaban for post hospital discharge in patients with OCVID-19. Enrollment closed 6/2022.

Prior and current grants include: 

1. NIH NHLBI Institutional K12 
2. NIH NHLBI K01 
3. NIH NHLBI R01 
4. American Society of Hematology Scholar Award 
5. Longer Life Foundation Grant 

Biosketch

Education

• 2012-2011: MPHS (Master Population Health Science), Washington University School of Medicine, St. Louis, MO
• 2007-2003: MD, University of Missouri-Columbia, Columbia, MO
• 2003-1999: BS in Biology (magna cum laude), University of Missouri-Columbia, Columbia, MO

Post-Graduate Training

• 2013-2010: Hematology/Oncology Fellow, Washington University School of Medicine, St. Louis, MO
• 2010-2007: Internal Medicine Resident, University of Pittsburgh Medical Center, Pittsburgh, PA

Academic Positions

• 2023 – Current: Associate Professor, Hematology Division, Washington University in St. Louis
• 2016-2022: Assistant Professor, Hematology Division, Washington University in St. Louis
• 2013 – Current: Staff Physician, Hematology/Oncology, John Cochran Veterans Medical Center
• 2013-2016: Instructor of Medicine, Hematology Division, Washington University in St. Louis

University & Hospital Appointments & Committees

• 2023-2024: DOM Clinical Research Council, Hematology Representative/Member
• 2022 – Current: DOM Well-Being Committee, Hematology Representative/Member
• 2020 – Current: Pulmonary Embolism Response Team (PERT) Steering Committee
• 2019 – Current: Wellness Co-Chair, Hematology/Oncology Fellowship Program
• 2018-2022: Division of Hematology Clinical Faculty Recruitment Leader
• 2018-2020: Pulmonary Embolism Response Team (PERT) Working Group
• 2018-2018: Barnes Jewish Hospital Warfarin Working Group
• 2017-current: St. Louis Veterans Administration Medical Center Transfusion Committee, Member
• 2017-2018: Hematology Therapy Validation development, Epic
• 2016-2018: Washington University Department of Medicine Leader, Development of Inpatient Epic
• 2014-2018: Barnes Jewish Hospital Clinical Panel, Hematology Formulary Working Group

Board Certification

• 2014: American Board of Internal Medicine, Hematology
• 2013: American Board of Internal Medicine, Oncology
• 2010: American Board of Internal Medicine, Internal Medicine

Honors & Awards

• 2024-2022: American Society of Hematology, ASH Scholar Award
• 2012: American Society of Hematology, Clinical Research Training Institute
• 2011: American Society of Hematology, Abstract Award, Trainee
• 2003: Phi Beta Kappa National Honor Society
• 2002: Mortar Board Honor Society
• 2000: Phi Eta Sigma National Honor Society
• 2000: Golden Key National Honor Society

Editorial Boards

• 2024-current Editorial Board: Blood
• 2024-current Reviewer: Chest
• 2024-current Editorial Board: Journal of Thrombosis and Haemostasis
• 2022-current Associate Editor: Research and Practice in Thrombosis and Haemostasis
• 2021-2022 Editorial Board: Research and Practice in Thrombosis and Haemostasis2019-
• 2020 Reviewer: Journal of Geriatric Oncology
• 2020-current Reviewer: Annals of Internal Medicine
• 2020-current Reviewer: Blood Advances
• 2020-2024 Reviewer: Journal of Thrombosis and Haemostasis
• 2020-2022 Reviewer: Research and Practice in Thrombosis and Haemostasis
• 2020-2024 Reviewer: Blood
• 2019-current Reviewer: American Journal of Hematology

National Scientific Panels

• 2024–2026: Co-Director, American Society of Hematology Clinical Research Training Program MMENA 2025 (Mediterranean, Middle East, Northern Africa)
• 2023–2026: American Society of Hematology Clinical Research Training Institute, Steering Committee
• 2023 – Current: International Society on Thrombosis and Haemostasis: Hemostasis and Malignancy, Subcommittee Chair
• 2020 – Current: American Society of Hematology Clinical Research Training Institute, Faculty
• 2020 – 2023: International Society on Thrombosis and Haemostasis: Hemostasis and Malignancy, Subcommittee Co-Chair
• 2020 – Current: American Society of Hematology: COVID Coagulopathy Guideline Panel
• 2020-2023: American Society of Hematology Subcommittee on Clinical Trials

Professional Societies

• 2018-present: Hemostasis and Thrombosis Research Society
• 2017-present: International Society on Thrombosis and Haemostasis
• 2010-present: American Society of Hematology
• 2010-2020: American Society of Clinical Oncology

Selected Publications

• Afzal A, Gage BF, Suhong L, Schoen MW, Korenblat K, Sanfilippo KM. Different risks of hemorrhage in patients with elevated international normalized ratio from chronic liver disease versus warfarin therapy, a population-based retrospective cohort study. J Thromb Haemost. 2022;20(7):1610-1617. DOI: 10.1111/jth.15743
• Bria KE, Gage BF, Gutierrez A, et al. Time-to-start of anticoagulant therapy and mortality in pulmonary embolism. J Thromb Haemost. 2026;24(9):3240-3246. DOI: 10.1016/j.jtha.2026.06.014
• Mahmoud A, Luo S, Gage BF, et al. Association Between Anticoagulant-Related Bleeding and Mortality in Patients With Solid Tumors and Cancer-Associated Venous Thromboembolism. Am J Hematol. 2025;100(3):535-538. DOI: 10.1002/ajh.27588
• Afzal A, Suhong L, Mahmoud A, Gage BF, Sanfilippo KM. Anticoagulant Therapy and Bleeding-Related Hospitalizations in Patients With Cancer: A National Cohort Study. Am J Hematol. Published online September 7, 2026. DOI: 10.1002/ajh.70491
• Loncharich A, Gage BF, Luo S, et al. Risk factors for anticoagulant-related bleeding in cancer: traditional and cancer-specific factors. Blood Vessel Thromb Hemost. 2025;3(1):100116. Published 2025 Oct 9. DOI: 10.1016/j.bvth.2025.100116